Cytokinetics Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Cytokinetics (CYTK) Misses Q3 EPS by 13c
November 6, 2024 4:01 PM ESTCytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.36), $0.13 worse than the analyst estimate of ($1.23). Revenue for the quarter came in at $463 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
... More